Skip Nav Destination
Issues
15 April 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Perspective
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Gary J. Kelloff; John M. Hoffman; Bruce Johnson; Howard I. Scher; Barry A. Siegel; Edward Y. Cheng; Bruce D. Cheson; Joyce O'Shaughnessy; Kathryn Z. Guyton; David A. Mankoff; Lalitha Shankar; Steven M. Larson; Caroline C. Sigman; Richard L. Schilsky; Daniel C. Sullivan
Reviews
Human Cancer Biology
Lack of Telomerase Activity in Lung Carcinoids Is Dependent on Human Telomerase Reverse Transcriptase Transcription and Alternative Splicing and Is Associated with Long Telomeres
Nadia Zaffaroni; Raffaella Villa; Ugo Pastorino; Rosalia Cirincione; Matteo Incarbone; Marco Alloisio; Maria Curto; Silvana Pilotti; Maria Grazia Daidone
Colocalization of the Tetraspanins, CO-029 and CD151, with Integrins in Human Pancreatic Adenocarcinoma: Impact on Cell Motility
Sabine Gesierich; Claudia Paret; Dagmar Hildebrand; Jürgen Weitz; Kaspar Zgraggen; Friedrich H. Schmitz-Winnenthal; Vaclav Horejsi; Osamu Yoshie; Dorothee Herlyn; Leonie K. Ashman; Margot Zöller
Imaging, Diagnosis, Prognosis
High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non–Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy
Joe Y. Chang; Ritsuko Komaki; Ryohei Sasaki; Zhongxing Liao; Craig W. Stevens; Charles Lu; Frank V. Fossella; Pamela K. Allen; James D. Cox; Margaret R. Spitz; Xifeng Wu
EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCycler
Hidefumi Sasaki; Katsuhiko Endo; Akimitsu Konishi; Minoru Takada; Masaaki Kawahara; Keiji Iuchi; Akihide Matsumura; Meinoshin Okumura; Hisaichi Tanaka; Tomoya Kawaguchi; Toshiki Shimizu; Hiroshi Takeuchi; Motoki Yano; Ichiro Fukai; Yoshitaka Fujii
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Yuichiro Ohigashi; Masayuki Sho; Yukishige Yamada; Yoshikazu Tsurui; Kaoru Hamada; Naoya Ikeda; Takashi Mizuno; Ryo Yoriki; Hisanori Kashizuka; Katsunari Yane; Fumihiko Tsushima; Noriko Otsuki; Hideo Yagita; Miyuki Azuma; Yoshiyuki Nakajima
Expression Levels of TEL, AML1, and the Fusion Products TEL-AML1 and AML1-TEL versus Drug Sensitivity and Clinical Outcome in t(12;21)-Positive Pediatric Acute Lymphoblastic Leukemia
Wendy A.G. Stams; Monique L. den Boer; H. Berna Beverloo; Jules P.P. Meijerink; Elisabeth R. van Wering; Gritta E. Janka-Schaub; Rob Pieters
N1,N12-Diacetylspermine as a Sensitive and Specific Novel Marker for Early- and Late-Stage Colorectal and Breast Cancers
Kyoko Hiramatsu; Keiichi Takahashi; Taturo Yamaguchi; Hiroshi Matsumoto; Hidenori Miyamoto; Souichi Tanaka; Chikako Tanaka; Yoshiko Tamamori; Mari Imajo; Masashi Kawaguchi; Masakazu Toi; Takeo Mori; Masao Kawakita
Cancer Therapy: Clinical
Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer Patients
Rudolf Napieralski; Katja Ott; Markus Kremer; Katja Specht; Holger Vogelsang; Karen Becker; Martina Müller; Florian Lordick; Ulrich Fink; Jörg Rüdiger Siewert; Heinz Höfler; Gisela Keller
Cancer Therapy: Preclinical
Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models
Debra Ferguson; Luis E. Rodriguez; Joann P. Palma; Marion Refici; Kenneth Jarvis; Jacqueline O'Connor; Gerard M. Sullivan; David Frost; Kennan Marsh; Joy Bauch; Haiying Zhang; Nan-Horng Lin; Saul Rosenberg; Hing L. Sham; Ingrid B.J.K. Joseph
Development of β-Lapachone Prodrugs for Therapy Against Human Cancer Cells with Elevated NAD(P)H:Quinone Oxidoreductase 1 Levels
Kathryn E. Reinicke; Erik A. Bey; Melissa S. Bentle; John J. Pink; Stephen T. Ingalls; Charles L. Hoppel; Rosana I. Misico; Gisela M. Arzac; Gerardo Burton; William G. Bornmann; Damon Sutton; Jinming Gao; David A. Boothman
Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2
Kazuhiro Motoki; Eiji Mori; Atsushi Matsumoto; Mayumi Thomas; Takafumi Tomura; Robin Humphreys; Vivian Albert; Mari Muto; Hitoshi Yoshida; Masami Aoki; Taro Tamada; Ryota Kuroki; Hideaki Yoshida; Isao Ishida; Carl F. Ware; Shiro Kataoka
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.